Selective inhibition of complement membrane attack complex and C3 convertase by low molecular weight components of aurintricarboxylic acid synthesis complex

摘要

A component of the aurintricarboxylic acid complex with a molecular weight of less than 1 kilodalton is used to selectively inhibit complement membrane attack complexes in mammalian species, preferably humans. Preferred inhibitors are aurin tricarboxylic acid, aurine adracarboxylic acid, and aurin hexacarboxylic acid. Preferred diseases to be treated by selective inhibition of complement membrane attack complexes are age-related macular degeneration, Alzheimer's disease, atherosclerosis, rheumatoid arthritis, paroxysmal nocturnal hemoglobinuria, malaria infection, and Multiple sclerosis.